Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1YVZT)

Drug Name
Rituximab Drug Info
Indication
Disease Entry ICD 11 Status REF
Central nervous system non-hodgkin lymphoma Approved [1]
Eosinophilic granulomatosis with polyangiitis 4A44.A2 Approved [2]
Hepatosplenic T-cell lymphoma Approved [3]
Idiopathic thrombocytopenic purpura 3B64.10 Approved [4]
Large granular lymphocytic leukemia 2A90.1 Approved [5]
Leukemia Approved [6]
Lupus nephritis 4A40.0Y Approved [7]
Lymphoproliferative syndrome Approved [8]
Lymphosarcoma Approved [9]
MALT lymphoma Approved [10]
Nodal marginal zone lymphoma 2A85.0 Approved [11]
Non-hodgkin lymphoma 2B33.5 Approved [12]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified Approved [13]
Prolymphocytic leukaemia 2A82.1 Approved [14]
Recurrent adult burkitt lymphoma 2A85.6 Approved [15]
Small intestine lymphoma Approved [16]
Small lymphocytic lymphoma 2A82.0 Approved [17]
Splenic marginal zone lymphoma Approved [18]
Testicular lymphoma Approved [19]
Thrombotic thrombocytopenic purpura 3B64.14 Approved [20]
Waldenstrom macroglobulinemia 2A85.4 Approved [21]
Pemphigus vulgaris EB40 Phase 3 [22]
Haematological malignancy 2B33.Y Phase 1 [23]
B-cell neoplasm Investigative [24]
Cross-matching ID
TTD Drug ID
DM1YVZT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [28]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [29]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [30]
Ibritumomab DMG594T Non-hodgkin lymphoma 2B33.5 Approved [31]
Ublituximab DMHTY9W Multiple sclerosis 8A40 Approved [32]
Tositumomab DMMYZ3D Non-hodgkin lymphoma 2B33.5 Approved [31]
Obinutuzumab DM3BVAE Chronic lymphocytic leukaemia 2A82.0 Approved [33]
Ofatumumab DM295PR Chronic lymphocytic leukaemia 2A82.0 Approved [34]
Ocrelizumab DMEZ2KH Diffuse large B-cell lymphoma 2A81 Approved [35]
Glofitamab DM45HT6 Diffuse large B-cell lymphoma 2A81 Approved [36]
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [28]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [29]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [30]
Ibritumomab DMG594T Non-hodgkin lymphoma 2B33.5 Approved [31]
Ublituximab DMHTY9W Multiple sclerosis 8A40 Approved [32]
Tositumomab DMMYZ3D Non-hodgkin lymphoma 2B33.5 Approved [31]
Obinutuzumab DM3BVAE Chronic lymphocytic leukaemia 2A82.0 Approved [33]
Ofatumumab DM295PR Chronic lymphocytic leukaemia 2A82.0 Approved [34]
Ocrelizumab DMEZ2KH Diffuse large B-cell lymphoma 2A81 Approved [35]
Glofitamab DM45HT6 Diffuse large B-cell lymphoma 2A81 Approved [36]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Affected By Tumor necrosis factor (TNF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indomethacin DMSC4A7 Bursitis Approved [37]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [38]
Fructose DM43AN2 Vomiting MD90 Approved [26]
Ketoprofen DMRKXPT Bursitis Approved [26]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [39]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [40]
Baclofen DM0QV1J Multiple sclerosis 8A40 Approved [41]
Gefitinib DM15F0X Colon adenocarcinoma Approved [42]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [43]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [45]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [46]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [47]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [48]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [49]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [50]
Infliximab DMH7OIA Crohn disease DD70 Approved [51]
Cetuximab DMLNCE0 Colorectal cancer 2B91.Z Approved [52]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [53]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-8 (CXCL8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [55]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [56]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [57]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [58]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [59]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [60]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [61]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [62]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [63]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-6 (IL6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [64]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [65]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [66]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [58]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [67]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [60]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [68]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [69]
Methotrexate DM2TEOL Anterior urethra cancer Approved [64]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Not Available [25]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Drug Response [26]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Drug Response [26]
Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A) OTOWXCF3 FCG3A_HUMAN Drug Response [27]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Drug Response [26]

References

1 How we treat primary central nervous system lymphoma. ESMO Open. 2021 Aug;6(4):100213.
2 Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019 Oct;68(4):430-436.
3 Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. Diagn Pathol. 2014 Mar 12;9:58.
4 Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019 Dec 1;57(4):273-283.
5 Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
6 Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80.
7 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
8 Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation. Autoimmun Rev. 2023 Nov;22(11):103442.
9 Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
10 Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med. 2022 Dec 23;12(1):120.
11 Nodal marginal zone lymphoma. Leuk Lymphoma. 2014 Jun;55(6):1240-50.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
13 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
14 B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228.
15 Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2023 Mar;64(3):586-596.
16 Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24806.
17 Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043.
18 Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148.
19 First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72.
20 Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021 Feb 2;10(3):536.
21 Waldenstr?m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-358.
22 ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health.
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780).
24 Diffuse Large B-Cell Lymphoma and Related Entities. Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296.
25 [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
26 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
27 FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11.
28 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
29 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
30 Clinical pipeline report, company report or official report of Genmab.
31 Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
32 The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
34 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
35 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
36 Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959-1970.
37 Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
38 A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
39 CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
40 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
41 Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
42 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
43 Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
44 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
45 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
46 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
47 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
48 Human 3D multicellular microtissues: an upgraded model for the in vitro mechanistic investigation of inflammation-associated drug toxicity. Toxicol Lett. 2019 Sep 15;312:34-44.
49 Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
50 Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007 Dec;12(6):511-7. doi: 10.1080/10245330701562535.
51 Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009 Oct;68(10):1547-52. doi: 10.1136/ard.2008.096982. Epub 2008 Oct 17.
52 FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. doi: 10.1200/JCO.2006.08.8021.
53 Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
54 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
55 Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
56 Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
57 Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
58 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
59 Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
60 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
61 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
62 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
63 Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
64 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
65 Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.
66 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
67 Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
68 (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
69 Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.